Evidence map›Paper›PMID 38389894›Full record

ArticleRSC medicinal chemistry2024

Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1.

Minjie Deng, Yue Gao, Peipei Wang, Wenjing Du, Gaoya Xu, Jia Li, Yubo Zhou, Tao Liu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Minjie DengZJU-ENS Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University Zijingang Campus Hangzhou 310058 P.R. China lt601@zju.edu.cn.
Yue GaoSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine Nanjing 210023 P.R. China.
Peipei WangSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine Nanjing 210023 P.R. China.
Wenjing DuZJU-ENS Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University Zijingang Campus Hangzhou 310058 P.R. China lt601@zju.edu.cn.
Gaoya XuSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine Nanjing 210023 P.R. China.
Jia LiSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine Nanjing 210023 P.R. China.
Yubo ZhouState Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203 P.R. China ybzhou@simm.ac.cn.
Tao LiuZJU-ENS Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University Zijingang Campus Hangzhou 310058 P.R. China lt601@zju.edu.cn.ORCID https://orcid.org/0000-0002-2315-2475
Nanjing University of Chinese Medicine · CNZhejiang University · CNChinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we discover an FLT3/CHK1 dual inhibitor (30) that exhibits excellent kinase potency and antiproliferative activity against MV4-11 cells. Simultaneously, 30 possesses high selectivity over c-Kit enzyme and low hERG inhibitory ability. Compound 30, meanwhile, overcomes varied resistance in BaF3 cell lines carrying FLT3-TKD and FLT3-ITD mutations. Moreover, 30 demonstrates favorable oral PK properties and kinase selectivity. These conclusions support that compound 30 may be a promising potential FLT3/CHK1 dual agent for further development.

Identifiers

PMID38389894
PMCPMC10880922
OpenAlexW4389445943

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.